Clinical Trial Update: Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) [Phase 3]

View source ↗

Summary

Phase III clinical trial evaluating immunogenicity and safety of PT Bio Farma's in-house recombinant hepatitis B vaccine in Indonesia; currently not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• In-House Recombinant Hepatitis B Vaccine (recombinant hepatitis B vaccine)

Snippet

Sponsor: PT Bio Farma | Conditions: Vaccine Reaction, Vaccine Adverse Reaction | Phase 3 | Status: NOT_YET_RECRUITING